- Home
- FREY vs AVIR Comparison
FREY vs AVIR Comparison
Compare FREY & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- AVIR
- Stock Information
- Founded
- FREY 2018
- AVIR 2012
- Country
- FREY Luxembourg
- AVIR United States
- Employees
- FREY N/A
- AVIR N/A
- Industry
- FREY Industrial Machinery/Components
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- FREY Miscellaneous
- AVIR Health Care
- Exchange
- FREY Nasdaq
- AVIR Nasdaq
- Market Cap
- FREY 293.4M
- AVIR 247.5M
- IPO Year
- FREY N/A
- AVIR 2020
- Fundamental
- Price
- FREY $1.69
- AVIR $2.94
- Analyst Decision
- FREY
- AVIR Hold
- Analyst Count
- FREY 0
- AVIR 1
- Target Price
- FREY N/A
- AVIR $6.88
- AVG Volume (30 Days)
- FREY 3.6M
- AVIR 227.6K
- Earning Date
- FREY 11-06-2024
- AVIR 11-07-2024
- Dividend Yield
- FREY N/A
- AVIR N/A
- EPS Growth
- FREY N/A
- AVIR N/A
- EPS
- FREY N/A
- AVIR N/A
- Revenue
- FREY N/A
- AVIR N/A
- Revenue This Year
- FREY N/A
- AVIR N/A
- Revenue Next Year
- FREY $414.23
- AVIR N/A
- P/E Ratio
- FREY N/A
- AVIR N/A
- Revenue Growth
- FREY N/A
- AVIR N/A
- 52 Week Low
- FREY $0.91
- AVIR $2.86
- 52 Week High
- FREY $2.85
- AVIR $4.60
- Technical
- Relative Strength Index (RSI)
- FREY 44.18
- AVIR 34.81
- Support Level
- FREY $2.03
- AVIR $2.86
- Resistance Level
- FREY $2.66
- AVIR $3.54
- Average True Range (ATR)
- FREY 0.20
- AVIR 0.14
- MACD
- FREY -0.10
- AVIR -0.03
- Stochastic Oscillator
- FREY 3.12
- AVIR 11.76
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).